Explore

Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses
Trendline Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Trendline Trendline
Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments

Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments

Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Trendline Trendline
Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials

Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials

Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials
Trendline Trendline
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026
Trendline Trendline
Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results
Trendline Trendline
Silexion Therapeutics Advances Pancreatic Cancer Drug to Phase 2/3 Trials

Silexion Therapeutics Advances Pancreatic Cancer Drug to Phase 2/3 Trials

Silexion Therapeutics Advances Pancreatic Cancer Drug to Phase 2/3 Trials
Trendline Trendline
Longeveron Reports Q1 Financial Results and Strategic Updates

Longeveron Reports Q1 Financial Results and Strategic Updates

Longeveron Reports Q1 Financial Results and Strategic Updates